2-bromo-1-(1H-indazol-5-yl)ethan-1-one | 1283594-26-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 2-bromo-1-(1H-indazol-5-yl)ethan-1-one
• 英文别名: 2-bromo-1-(1H-indazol-5-yl)ethanone
• CAS: 1283594-26-2
• 化学式: C₉H₇BrN₂O
• 分子量: 239.071
• InChiKey: AQAYIBZGSIELDM-UHFFFAOYSA-N

物化性质

• 沸点：
  394.7±17.0 °C(Predicted)
• 密度：
  1.709±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-bromo-1-(1H-indazol-5-yl)ethan-1-one 、 N-苄基硫脲 以 乙醇 为溶剂， 反应 24.0h， 生成 N-benzyl-4-(1H-indazol-5-yl)-1,3-thiazol-2-amine
  参考文献：
  名称：

  Scaffold oriented synthesis. Part 4: Design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing heterocycle forming and multicomponent reactions

  摘要：

  We report the synthesis and biological evaluation of 5-substituted indazoles as kinase inhibitors. The compounds were synthesized in a parallel synthesis fashion from readily available starting materials employing heterocycle forming and multicomponent reactions and were evaluated against a panel of kinase assays. Potent inhibitors were identified for Gsk3 beta, Rock2, and Egfr. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.001
• 作为产物：
  描述：

  吲唑-5-甲酸盐酸盐 在 4-二甲氨基吡啶 、 pyridinium hydrobromide perbromide 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 2-bromo-1-(1H-indazol-5-yl)ethan-1-one
  参考文献：
  名称：

  Scaffold oriented synthesis. Part 4: Design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing heterocycle forming and multicomponent reactions

  摘要：

  We report the synthesis and biological evaluation of 5-substituted indazoles as kinase inhibitors. The compounds were synthesized in a parallel synthesis fashion from readily available starting materials employing heterocycle forming and multicomponent reactions and were evaluated against a panel of kinase assays. Potent inhibitors were identified for Gsk3 beta, Rock2, and Egfr. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.001

文献信息

• [EN] PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDINONE ET DE PYRIMIDINONE COMME INHIBITEURS DU FACTEUR XIA
  申请人：ONO PHARMACEUTICAL CO

  公开号：WO2013093484A1

  公开（公告）日：2013-06-27

  The present invention provides compounds of the general formula (I), their salts and N- oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.

  本发明提供了一般式(I)的化合物，它们的盐和N-氧化物，以及它们的溶剂合物和前药（其中字符如描述中所定义）。一般式(I)的化合物是因子XIa的抑制剂，因此它们在预防和/或治疗血栓栓塞疾病方面是有用的。
• COMPOUNDS
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20150152112A1

  公开（公告）日：2015-06-04

  The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.

  本发明提供了一般式（I）的化合物，它们的盐和N-氧化物，以及它们的溶剂化物和前药（其中字符如描述中所定义）。一般式（I）的化合物是因子XIa的抑制剂，因此它们在预防和/或治疗血栓性疾病方面非常有用。
• 7,8-DIHYDROBENZO[E]PYRIDO[3,4-C]AZOCINE-2,5(3H,6H)-DIONE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORS
  申请人：Janssen Pharmaceutica NV

  公开号：US20220389005A1

  公开（公告）日：2022-12-08

  The present invention is directed to 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.

  本发明涉及7,8-二氢苯并[e]吡啶[3,4-c]氮杂环-2,5(3H,6H)-二酮衍生物、立体异构体、同位素拓扑构型、同位素拓扑异构体和其药学上可接受的盐，含有该化合物的制药组合物以及在治疗和/或预防血栓栓塞性疾病、炎症性疾病以及涉及血浆卡利肌酶活性的疾病或病况中使用该化合物的用途。
• Pyrimidinone and its derivatives inhibiting factor XIa
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US10717738B2

  公开（公告）日：2020-07-21

  The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.

  本发明提供通式(I)化合物、其盐类和N-氧化物，以及其溶解物和原药（其中特征如描述中所定义）。通式（I）化合物是因子 XIa 的抑制剂，因此可用于预防和/或治疗血栓栓塞性疾病。
• The impact of binding site waters on the activity/selectivity trade-off of Janus kinase 2 (JAK2) inhibitors
  作者：Attila Egyed、Dávid Bajusz、György M. Keserű

  DOI：10.1016/j.bmc.2019.02.029

  日期：2019.4

  Structure based optimization of B39, an indazole-based low micromolar JAK2 virtual screening hit is reported. Analysing the effect of certain modifications on the activity and selectivity of the analogues suggested that these parameters are influenced by water molecules available in the binding site. Simulation of water networks in combination with docking enabled us to identify the key waters and to optimize our primary hit into a low nanomolar JAK2 lead with promising selectivity over JAK1.